Clinical features and prognosis of cardiac metastatic tumors
Abstract Background This study aimed to explore the clinical features and prognosis of cardiac metastatic tumors. In addition, whether continuing antitumor therapy after the development of cardiac metastases can benefit patients and the response of cardiac metastases were investigated. Methods A ret...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11733-1 |
| _version_ | 1797388311397924864 |
|---|---|
| author | Zhongqiao Lin Huazhen Xiao Jun Liu Ling Chen Huishan Zhang Yufang Huang Yu Chen Jing Lin |
| author_facet | Zhongqiao Lin Huazhen Xiao Jun Liu Ling Chen Huishan Zhang Yufang Huang Yu Chen Jing Lin |
| author_sort | Zhongqiao Lin |
| collection | DOAJ |
| description | Abstract Background This study aimed to explore the clinical features and prognosis of cardiac metastatic tumors. In addition, whether continuing antitumor therapy after the development of cardiac metastases can benefit patients and the response of cardiac metastases were investigated. Methods A retrospective analysis was conducted on patients with malignancies who were admitted to Fujian Cancer Hospital and Fujian Provincial Hospital from January 2007 to September 2022, and the follow-up period ended in March 2023. Clinical data were gathered, treatment efficacy was evaluated, and survival analysis was performed. Results After the patients developed cardiac metastasis, the overall 30-day, 3-month, 6-month, and 12-month survival rates were 85.00%, 59.00%, 51.00% and 38.00%, respectively. With continued treatment, the average survival time was 27.33 months (95% confidence interval [CI]: 16.88–37.79), which exceeded the 6.6 months (95% confidence interval [CI]: 0.03–13.69) observed for patients who withdrew from treatment (P < 0.001). The responses of cardiac metastases corresponded to the responses of the primary tumors. Patients with a cardiac response had a median survival time of 55.60 months, which exceeded the 13.40 months observed for those without a cardiac response. However, there was no significant difference (P = 0.375). Conclusions In conclusion, continuing antitumor therapy after the development of cardiac metastases can significantly prolong patient survival. Cardiac metastases and primary tumors respond consistently to antitumor treatment. The risk of death due to heart failure in cancer patients with cardiac metastases needs to be further investigated. |
| first_indexed | 2024-03-08T22:38:56Z |
| format | Article |
| id | doaj.art-fbd281a7020343ab91bd0d1d0d6d90d3 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-08T22:38:56Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-fbd281a7020343ab91bd0d1d0d6d90d32023-12-17T12:20:27ZengBMCBMC Cancer1471-24072023-12-0123111010.1186/s12885-023-11733-1Clinical features and prognosis of cardiac metastatic tumorsZhongqiao Lin0Huazhen Xiao1Jun Liu2Ling Chen3Huishan Zhang4Yufang Huang5Yu Chen6Jing Lin7Phase I Clinical Trial Ward, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalPhase I Clinical Trial Ward, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalAbstract Background This study aimed to explore the clinical features and prognosis of cardiac metastatic tumors. In addition, whether continuing antitumor therapy after the development of cardiac metastases can benefit patients and the response of cardiac metastases were investigated. Methods A retrospective analysis was conducted on patients with malignancies who were admitted to Fujian Cancer Hospital and Fujian Provincial Hospital from January 2007 to September 2022, and the follow-up period ended in March 2023. Clinical data were gathered, treatment efficacy was evaluated, and survival analysis was performed. Results After the patients developed cardiac metastasis, the overall 30-day, 3-month, 6-month, and 12-month survival rates were 85.00%, 59.00%, 51.00% and 38.00%, respectively. With continued treatment, the average survival time was 27.33 months (95% confidence interval [CI]: 16.88–37.79), which exceeded the 6.6 months (95% confidence interval [CI]: 0.03–13.69) observed for patients who withdrew from treatment (P < 0.001). The responses of cardiac metastases corresponded to the responses of the primary tumors. Patients with a cardiac response had a median survival time of 55.60 months, which exceeded the 13.40 months observed for those without a cardiac response. However, there was no significant difference (P = 0.375). Conclusions In conclusion, continuing antitumor therapy after the development of cardiac metastases can significantly prolong patient survival. Cardiac metastases and primary tumors respond consistently to antitumor treatment. The risk of death due to heart failure in cancer patients with cardiac metastases needs to be further investigated.https://doi.org/10.1186/s12885-023-11733-1TumorCardiac metastasisCancer survivorshipCardiac functionEchocardiographyEfficacy evaluation |
| spellingShingle | Zhongqiao Lin Huazhen Xiao Jun Liu Ling Chen Huishan Zhang Yufang Huang Yu Chen Jing Lin Clinical features and prognosis of cardiac metastatic tumors BMC Cancer Tumor Cardiac metastasis Cancer survivorship Cardiac function Echocardiography Efficacy evaluation |
| title | Clinical features and prognosis of cardiac metastatic tumors |
| title_full | Clinical features and prognosis of cardiac metastatic tumors |
| title_fullStr | Clinical features and prognosis of cardiac metastatic tumors |
| title_full_unstemmed | Clinical features and prognosis of cardiac metastatic tumors |
| title_short | Clinical features and prognosis of cardiac metastatic tumors |
| title_sort | clinical features and prognosis of cardiac metastatic tumors |
| topic | Tumor Cardiac metastasis Cancer survivorship Cardiac function Echocardiography Efficacy evaluation |
| url | https://doi.org/10.1186/s12885-023-11733-1 |
| work_keys_str_mv | AT zhongqiaolin clinicalfeaturesandprognosisofcardiacmetastatictumors AT huazhenxiao clinicalfeaturesandprognosisofcardiacmetastatictumors AT junliu clinicalfeaturesandprognosisofcardiacmetastatictumors AT lingchen clinicalfeaturesandprognosisofcardiacmetastatictumors AT huishanzhang clinicalfeaturesandprognosisofcardiacmetastatictumors AT yufanghuang clinicalfeaturesandprognosisofcardiacmetastatictumors AT yuchen clinicalfeaturesandprognosisofcardiacmetastatictumors AT jinglin clinicalfeaturesandprognosisofcardiacmetastatictumors |